



# Inrebic in India

*The CDSCO named-patient coordination pathway — indicative 2026*

ONCOLOGY · INTERMEDIATE / HIGH-RISK MYELOFIBROSIS

## The clinical situation

Inrebic (fedratinib) is an oral selective JAK2 inhibitor FDA-approved for adults with intermediate-2 or high-risk primary or secondary myelofibrosis (post-PV or post-ET MF). Manufactured by Bristol Myers Squibb. Dosing is 400 mg once daily, with mandatory thiamine level monitoring at baseline and periodically due to a boxed warning for Wernicke's encephalopathy. Pre-treatment workup covers CBC, LFTs, thiamine level, amylase/lipase, hepatitis B screen, TB screen, and IPSS/DIPSS risk scoring per FDA labelling.

### The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your haematologist documents MF subtype, risk score, prior ruxolitinib exposure, and Inrebic rationale.
- 2 Baseline workup.** CBC, LFTs, thiamine level, amylase/lipase, HBV/TB screen per FDA labelling.
- 3 CDSCO named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, Wernicke's-encephalopathy monitoring plan, and chain-of-custody commitment.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with controlled-ambient shipment.
- 5 Arrival & first dose.** Dispensing pharmacy releases the first 30-day supply; monthly refill cadence and monitoring established.

### Indicative economics

**Reference US cash-pay range:** USD 22,000–26,000 per month of Inrebic (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

### Indicative first-dose timing

**7–14 days** from a complete CDSCO application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody from BMS authorised distribution.

**Documentation.** Physician kit tailored to CDSCO review, with MF risk-score and thiamine-monitoring boxed-warning annex.

**Logistics.** Controlled-ambient internationally tracked shipment. **Concierge case lead.** Named point of contact for family and physician through monthly refills. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Inrebic × India first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/inrebic-india.html](https://reservemed.com/access-guides/inrebic-india.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team